These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
26. [Importance of ANCAs in the pathogenesis of chronic inflammatory bowel diseases]. Müller-Ladner U; Andus T; Lang B; Gross V Verh Dtsch Ges Pathol; 1996; 80():215. PubMed ID: 9065008 [No Abstract] [Full Text] [Related]
27. Serum antibodies for the diagnosis of inflammatory bowel disease: ANCA for ulcerative colitis and ASCA for Crohn's disease. Tecnologica MAP Suppl; 1999 Jun; ():18-20. PubMed ID: 10848041 [No Abstract] [Full Text] [Related]
28. Anti-lactoferrin antibodies and other types of ANCA in ulcerative colitis, primary sclerosing cholangitis, and Crohn's disease. Peen E; Almer S; Bodemar G; Rydén BO; Sjölin C; Tejle K; Skogh T Gut; 1993 Jan; 34(1):56-62. PubMed ID: 8432453 [TBL] [Abstract][Full Text] [Related]
29. Antineutrophil antibodies in familial inflammatory bowel disease. Lee JC; Lennard-Jones JE; Cambridge G Gastroenterology; 1995 Feb; 108(2):428-33. PubMed ID: 7835584 [TBL] [Abstract][Full Text] [Related]
30. Segregation of pANCA antigenic recognition by DNase treatment of neutrophils: ulcerative colitis, type 1 autoimmune hepatitis, and primary sclerosing cholangitis. Vidrich A; Lee J; James E; Cobb L; Targan S J Clin Immunol; 1995 Nov; 15(6):293-9. PubMed ID: 8576315 [TBL] [Abstract][Full Text] [Related]
32. New serological markers for inflammatory bowel disease are associated with earlier age at onset, complicated disease behavior, risk for surgery, and NOD2/CARD15 genotype in a Hungarian IBD cohort. Papp M; Altorjay I; Dotan N; Palatka K; Foldi I; Tumpek J; Sipka S; Udvardy M; Dinya T; Lakatos L; Kovacs A; Molnar T; Tulassay Z; Miheller P; Norman GL; Szamosi T; Papp J; ; Lakatos PL Am J Gastroenterol; 2008 Mar; 103(3):665-81. PubMed ID: 18047543 [TBL] [Abstract][Full Text] [Related]
33. [Anticytoplasmic auto-antibodies of polynuclear neutrophils: a common biologic marker in hemorrhagic rectocolitis and primary sclerosing cholangitis]. Jacquot S Gastroenterol Clin Biol; 1991; 15(12):990-1. PubMed ID: 1783264 [No Abstract] [Full Text] [Related]
34. Distinguishing between anti-neutrophil cytoplasmic antibody patterns in inflammatory bowel disease: is the "atypical pattern" adding more information? Barahona-Garrido J; Hernández-Calleros J; Cabiedes J; Sarti HM; Torre A; Montaño-Loza AJ; Yamamoto-Furusho JK Am J Gastroenterol; 2009 Jul; 104(7):1854-5. PubMed ID: 19574983 [No Abstract] [Full Text] [Related]
35. HLA class II genes in primary sclerosing cholangitis and chronic inflammatory bowel disease: no HLA-DRw52a association in Swedish patients with sclerosing cholangitis. Zetterquist H; Broomé U; Einarsson K; Olerup O Gut; 1992 Jul; 33(7):942-6. PubMed ID: 1644334 [TBL] [Abstract][Full Text] [Related]
36. Neutrophil cytoplasmic antibodies: a link between primary sclerosing cholangitis and ulcerative colitis. Duerr RH; Targan SR; Landers CJ; LaRusso NF; Lindsay KL; Wiesner RH; Shanahan F Gastroenterology; 1991 May; 100(5 Pt 1):1385-91. PubMed ID: 2013383 [TBL] [Abstract][Full Text] [Related]
37. Novel anti-glycan antibodies related to inflammatory bowel disease diagnosis and phenotype. Seow CH; Stempak JM; Xu W; Lan H; Griffiths AM; Greenberg GR; Steinhart AH; Dotan N; Silverberg MS Am J Gastroenterol; 2009 Jun; 104(6):1426-34. PubMed ID: 19491856 [TBL] [Abstract][Full Text] [Related]
38. Anti-neutrophil antibodies in primary sclerosing cholangitis. Terjung B; Worman HJ Best Pract Res Clin Gastroenterol; 2001 Aug; 15(4):629-42. PubMed ID: 11492972 [TBL] [Abstract][Full Text] [Related]